| Business Summary | | Variagenics,
Inc.
is
engaged
in
the
development
and
commercialization
of
technologies
related
to
pharmacogenomics,
which
is
the
study
of
the
correlation
between
an
individual's
genetic
differences,
or
genetic
variability,
and
his
or
her
specific
response
to
a
drug.
The
most
common
form
of
this
genetic
variability
is
a
single
nucleotide
polymorphism
(SNP).
The
Company
uses
its
pharmacogenomics
technology,
expertise
and
proprietary
data
to
improve
and
enhance
drugs
in
development
and
to
identify
and
validate
new
drug
targets.
The
Company
also
intends
to
use
its
technology
to
bring
high-value
diagnostic
products
to
market.
Variagenics
is
a
pharmacogenomics
company
offering
a
full
range
of
solutions
to
support
key
steps
of
the
drug
discovery
and
development
process,
extending
from
drug
target
identification
through
clinical
trials
to
commercialization. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Variagenics,
Inc.
is
engaged
in
the
development
and
commercialization
of
technologies
about
pharmacogenomics,
a
study
of
the
correlation
between
an
individual's
genetic
differences,
and
his/her
specific
response
to
a
drug.
For
the
six
months
ended
6/30/01,
revenues
totaled
$2
million,
up
from
$276
thousand.
Net
loss
applicable
to
Common
fell
70%
to
$9.3
million.
Results
reflect
increased
collaboration
revenue
and
product
sales
as
well
as
the
absence
of
preferred
dividend
payments. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| David Housman, Ph.D., 54 Chairman
and Principal Scientific Advisor | -- | Taylor Crouch, 41 Pres,
CEO, Director | $391K | Richard Shea, 49 CFO,
VP of Fin. and Admin., Treasurer | 209K | R. Mark Adams, Ph.D. VP,
Bioinformatics | -- | Ann Bailey, 56 VP,
Diagnostic and Process Devel. | 210K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|